Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 6, 2020

Magstim acquires EGI product portfolio from Royal Philips

Magstim has acquired the product portfolio of Electrical Geodesics (EGI) from health technology company Royal Philips.

Magstim has acquired the product portfolio of Electrical Geodesics (EGI) from health technology company Royal Philips.

The company will acquire EGI hardware, software and sensor nets assets and start managing its global sales, service and support. Philips will support the transition until the end of this year.

EGI develops non-invasive multimodal technologies to monitor brain activity and provide transcranial electrical stimulation in brain research.

EGI’s proprietary dense array electroencephalography (EEG) technology collects data from more electrodes than conventional EEG. The technology is used to evaluate the electrical activity in the brain.

Developed by EGI, Geodesic Sensor Net (GSN) can produce high-resolution data and is used worldwide by neuroscience researchers.

Magstim Group CEO Lothar Krinke said: “This adds high-density EEG to our product portfolio, supporting more than 1,200 research labs and clinics that focus on mental health, brain disorders and cognitive neuroscience.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“Magstim has been pioneering and advancing transcranial magnetic stimulation for 30 years. High-density EEG closes the loop for the development of a comprehensive system for non-invasive neuromodulation. Magstim and EGI share a legacy and passion for innovation in neuroscience.”

Following the acquisition, Magstim plans to maintain a presence in EGI’s Oregon office supported by its global offices in the UK, Netherlands and Minneapolis, US.

The company is the pioneer of transcranial magnetic stimulation, a non-invasive, outpatient therapy cleared by the Food and Drug Administration (FDA) for major depressive disorder.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU